The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 05, 2019
Filed:
Dec. 11, 2017
Applicant:
Medtronic Ardian Luxembourg S.a.r.l., Luxembourg, LU;
Inventors:
Neil Barman, Menlo Park, CA (US);
Howard Levin, Teaneck, NJ (US);
Paul Sobotka, St. Paul, MN (US);
Mark Gelfand, New York, NY (US);
Assignee:
Medtronic Ardian Luxembourg S.a.r.l., Luxembourg, LU;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 18/14 (2006.01); A61B 18/08 (2006.01); A61N 1/36 (2006.01); A61N 1/32 (2006.01); A61B 18/00 (2006.01); A61B 18/02 (2006.01); A61B 18/04 (2006.01); A61K 31/165 (2006.01); A61K 31/198 (2006.01); A61K 31/4168 (2006.01); A61K 31/506 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
A61B 18/1492 (2013.01); A61B 18/02 (2013.01); A61B 18/04 (2013.01); A61B 18/082 (2013.01); A61K 31/165 (2013.01); A61K 31/198 (2013.01); A61K 31/4168 (2013.01); A61K 31/506 (2013.01); A61K 49/0004 (2013.01); A61N 1/327 (2013.01); A61N 1/36057 (2013.01); A61N 1/36117 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00702 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/0212 (2013.01); A61N 1/326 (2013.01);
Abstract
Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.